Name

375 - Résultats à 2 ans des études de phase 3 de brolucizumab dans la DMLA humide : études HAWK et HARRIER

Ninety-six-week (wk) results from two prospective studies evaluating the efficacy and safety of brolucizumab vs aflibercept for nAMD.

Patients were randomized 1:1:1 to brolucizumab 3/6 mg or aflibercept 2 mg (HAWK) or 1:1 to brolucizumab 6 mg or aflibercept 2 mg (HARRIER). After the loading phase, brolucizumab patients received q12w dosing with an option to adjust to q8w at predefined disease activity assessment visits; aflibercept was dosed q8w.

Brolucizumab was non-inferior to aflibercept in mean BCVA change from baseline at 48 wks (primary endpoint) with superiority in key anatomical outcomes. Visual and anatomical improvements were sustained with brolucizumab over 96 wks with a significant proportion of patients remaining on a q12w dosing interval. Overall ocular and non-ocular adverse event rates of brolucizumab were comparable to aflibercept over 96-wks.

The visual and anatomical improvements were sustained with brolucizumab over 96 wks.

The visual and anatomical improvements were sustained with brolucizumab over 96 wks.